Hudson Vegas Investment Spv, L Sells 50,000 Shares of P3 Health Partners (NASDAQ:PIII) Stock

P3 Health Partners Inc. (NASDAQ:PIII) major shareholder Hudson Vegas Investment Spv, L sold 50,000 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $16.48, for a total value of $824,000.00. Following the transaction, the insider directly owned 48,959 shares of the company’s stock, valued at $806,844.32. This represents a 50.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

P3 Health Partners Trading Down 5.5%

NASDAQ:PIII traded down $0.68 during mid-day trading on Wednesday, hitting $11.69. 52,461 shares of the company’s stock traded hands, compared to its average volume of 567,255. The firm has a 50 day moving average of $10.97 and a two-hundred day moving average of $6.47. P3 Health Partners Inc. has a 12 month low of $1.52 and a 12 month high of $16.89. The firm has a market capitalization of $84.64 million, a price-to-earnings ratio of -0.35 and a beta of 1.63.

P3 Health Partners (NASDAQ:PIII) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($1.89) by $1.26. The business had revenue of $386.38 million during the quarter, compared to the consensus estimate of $377.80 million.

Wall Street Analysts Forecast Growth

Several research firms recently commented on PIII. TD Cowen reiterated a “hold” rating and set a $14.00 target price (up from $3.00) on shares of P3 Health Partners in a research note on Friday, May 22nd. Lake Street Capital reiterated a “buy” rating and issued a $23.00 target price on shares of P3 Health Partners in a research note on Tuesday. UBS Group set a $14.00 target price on shares of P3 Health Partners in a research note on Friday, May 15th. Wall Street Zen raised P3 Health Partners to a “hold” rating in a research report on Saturday, July 4th. Finally, Weiss Ratings upgraded P3 Health Partners from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, May 28th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $17.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in P3 Health Partners stock. Lido Advisors LLC purchased a new position in shares of P3 Health Partners Inc. (NASDAQ:PIII) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 10,748 shares of the company’s stock, valued at approximately $33,000. Lido Advisors LLC owned approximately 0.15% of P3 Health Partners at the end of the most recent reporting period. Hedge funds and other institutional investors own 7.75% of the company’s stock.

About P3 Health Partners

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.